Keyphrases
Metastatic Renal Cell Carcinoma (mRCC)
100%
Sunitinib
80%
Expert Recommendation
80%
Androgen Deprivation Therapy
70%
Prostate Cancer
66%
Renal Cancer
60%
Upper Tract Urothelial Carcinoma
60%
Patient Management
60%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
60%
Clear Cell Histology
53%
Systemic Treatment
50%
Prostate Cancer Patients
50%
Tumor
46%
CHAARTED
40%
Muscle-invasive Bladder Cancer
40%
High-grade Prostate Cancer
40%
Genitourinary Cancer
40%
First-line Managers
40%
Colon Cancer Recurrence
40%
Diagnostic Guide
40%
Weekly Docetaxel
40%
Genitourinary Tumors
40%
Hypoxia-inducible Factor Pathway
40%
Current Management
40%
Recent Advances
40%
Positron Emission Tomography
40%
Predictive Factors
40%
Estimated Glomerular Filtration Rate
40%
Diagnostic Methods
40%
Laparoscopic Approach
40%
Surgical Resection
40%
Clinical Trials
40%
Progression-free Survival
40%
Nephroureterectomy
40%
Cisplatin-based Chemotherapy
40%
Impaired Renal Function
40%
Radiation Therapy
40%
C-Myc
40%
Tyrosine Kinase Inhibitor
40%
New Advances
40%
Special Populations
40%
Docetaxel
40%
Abiraterone
40%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
36%
Overall Survival
33%
Non-clear Cell
33%
Cancer Bladder
33%
Therapeutic Potential
33%
Chemotherapy
33%
Quality of Life
33%
Medicine and Dentistry
Prostate Cancer
80%
Chemotherapy
80%
Clear Cell Renal Cell Carcinoma
77%
Sunitinib
69%
Recurrent Disease
60%
Kidney Metastasis
53%
Transitional Cell Carcinoma
53%
Quality of Life
53%
Surgery
48%
Systemic Therapy
48%
Clear Cell
42%
Neoplasm
41%
Hypoxia Inducible Factor
40%
Muscle Invasive Bladder Cancer
40%
Glomerular Filtration Rate
40%
Oncogene C Myc
40%
Kidney Function
40%
Nephroureterectomy
40%
Urogenital Tract Cancer
40%
Positron Emission Tomography
40%
Predictive Factor
40%
Cancer Recurrence
40%
Upper Urinary Tract
40%
Biological Marker
40%
Retroperitoneal Lymph Node Dissection
40%
Operation Duration
40%
Tyrosine-Kinase Inhibitor
40%
Testis Cancer
40%
Bladder Cancer
40%
Kidney Cancer
40%
Colon Carcinoma
40%
Diagnosis
40%
Urogenital Tract Tumor
40%
Clinical Trial
35%
Hydronephrosis
34%
Diseases
32%
Prothrombin
28%
Radiation Therapy
27%
Retrospective Study
27%
Molecular Research
26%
Cisplatin
26%
Progression Free Survival
22%
Bladder
20%
Biological Product
20%
Postoperative Complication
20%
Patient Selection
20%
Protein Concentrate Plus Carbohydrates Plus Lipids Plus Minerals Plus Vitamins
20%
Open Surgery
20%
Cystectomy
20%
Brain Metastasis
16%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
90%
Renal Cell Carcinoma
77%
Chemotherapy
73%
Androgen
70%
Sunitinib
69%
Docetaxel
60%
Transitional Cell Carcinoma
53%
Kidney Metastasis
53%
Castration Resistant Prostate Cancer
53%
Progression Free Survival
51%
Systemic Treatment
48%
Neoplasm
41%
Hypoxia Inducible Factor
40%
Biological Marker
40%
Urogenital Tract Tumor
40%
Hydronephrosis
40%
Protein Tyrosine Kinase Inhibitor
40%
Muscle Invasive Bladder Cancer
40%
Overall Survival
34%
Abiraterone
33%
Prothrombin
28%
Cisplatin
26%
Clinical Trial
21%
Biological Product
20%
Disease
19%
Biochemical Recurrence Free Survival
17%
Brain Metastasis
16%
Protein P53
13%
Cabazitaxel
13%
Bladder Cancer
13%
Fibroblast Growth Factor Receptor 3
13%
Cabozantinib
13%
Pazopanib
13%
Nivolumab
13%
Eribulin
13%
Carcinogenesis
13%
Phase II Trials
13%
Molecular Target
13%
Kidney Cancer
13%
Enzalutamide
13%
Vinflunine
13%
Urinary Tract Tumor
13%
Malignant Neoplasm
13%
Gonadorelin Derivative
11%
Hypoxia Inducible Factor 1
11%
Prostate Specific Antigen
11%
Biochemical Recurrence
11%
Everolimus
8%
Randomized Clinical Trial
8%
Mammalian Target of Rapamycin Inhibitor
8%
